Nothing is Better Than I-Mab ADR (IMAB) stock at the moment

With 1.77 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.59 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.9450 whereas the lowest price it dropped to was $1.7600. The 52-week range on IMAB shows that it touched its highest point at $5.29 and its lowest point at $1.16 during that stretch. It currently has a 1-year price target of $14.67. Beta for the stock currently stands at 1.13.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IMAB was down-trending over the past week, with a drop of -1.65%, but this was down by -20.09% over a month. Three-month performance surged to 11.18% while six-month performance fell -30.08%. The stock lost -64.34% in the past year, while it has lost -5.79% so far this year. EPS is expected to grow by 26.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -42.98%.

Float and Shares Shorts:

At present, 82.27 million IMAB shares are outstanding with a float of 81.69 million shares on hand for trading. On Jan 11, 2024, short shares totaled 1.51 million, which was 1.83% higher than short shares on Dec 14, 2023. In addition to Dr. Jingwu Zhang Zang M.D., Ph.D. as the firm’s Chairman & Founder, Mr. Raj Kannan serves as its CEO & Director.


An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. Over the past year, revenue came in at $122.11M while operating income stood at -$1.87B. EBITDA for the full year was -$1.99B.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IMAB since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With IMAB analysts setting a high price target of $18.00 and a low target of $8.00, the average target price over the next 12 months is $14.67. Based on these targets, IMAB could surge 905.59% to reach the target high and rise by 346.93% to reach the target low. Reaching the average price target will result in a growth of 719.55% from current levels.